Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT
2025-522323-10-00Phase 3Authorised
- Sponsor
- Central Denmark Region
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Cabergoline (Dostinex) with Placebo (2 arms). Planned start Nov 2025; status: authorised.
02
Drugs
cabergoline
03
Conditions
migraine
Beyond the preview
Go deeper on 2025-522323-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522323-10-00.